pocketful logo light
pocketful logo light
Laurus Labs Ltd logo

Laurus Labs Ltd

NSE: LAURUSLABS BSE: 540222

₹1419.80

(0.32%)

Mon, 15 Jun 2026, 10:09 pm

mtf coin illustrationMTF 5x

Laurus Labs Share Price Live Chart

1 Day

(0.32%)

No Result Found

Summary

  • Market Cap (in Cr)

    73506.87

  • Net Profit (in Cr)

    354.41

  • P/B

    7.40

  • Sector P/E

    33.76

  • P/E

    92.44

  • EV/EBITDA

    31.60

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    7.36

  • ROCE

    8.80

  • Debt/Equity

    0.62

  • EPS (TTM)

    16.46

  • Dividend Yield

    0.09

  • Book Value

    98.18

  • Interest Cover

    2.98

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters27.4927.4927.5927.5927.62
FII25.8226.5226.1625.7025.52
DII13.9712.4311.7311.9411.77
Public32.7133.5634.5134.7735.09
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

60.94

MACD

46.06

50 DMA

1239.24

200 DMA

1043.47

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1868.601577.201469.601285.801178.20994.40703.00
Fibonacci1577.201465.891397.111285.801174.491105.71994.40
Camarilla1442.131415.421388.711285.801335.291308.581281.87

Pivots Level: Classic

R3

+582.80

1868.60

R2

+291.40

1577.20

R1

+183.80

1469.60

1285.80
1285.80
Pivot Point
LTP: 1389.10

S1

-107.60

1178.20

S2

-291.40

994.40

S3

-582.80

703.00

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1393.38

  • 20-EMA

    1365.16

  • 30-EMA

    1329.11

  • 50-EMA

    1267.38

  • 100-EMA

    1171.53

  • 200-EMA

    1052.63

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
30 Apr 2026agm
30 Apr 2026board-meetingsAccounts, Quarterly Results, Interim Dividend
30 Apr 2026dividend₹1.20 Dividend /Share08 May 2026
23 Jan 2026board-meetingsQuarterly Results
23 Oct 2025dividend₹0.80 Dividend /Share31 Oct 2025
01 Oct 2025dividendInterim Dividend - Rs. - 0.831 Oct 2025
15 May 2025agm
24 Apr 2025dividend₹0.80 Dividend /Share09 May 2025
09 Apr 2025dividendInterim Dividend - Rs. - 0.809 May 2025
24 Oct 2024dividend₹0.40 Dividend /Share06 Nov 2024

Read More

Peer Comparison

Laurus Labs Ltd logo

Laurus Labs Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Laurus Labs Ltd About

Laurus Labs is equipped with an Active Pharma Ingredients (API).(Source : 202503 Annual Report Page No: 188)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2005

Headquarters

CEO

Ravindranath Kancherla

Employees

Contact

Website icon

Website

http://www.lauruslabs.com

Email icon

Email

secretarial@lauruslabs.com; info@lauruslabs.com

Phone icon

Phone

91-891-3061222

Location icon

Location

Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

Read More

Laurus Labs Ltd Company History

YearHistory
2020
  • Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States.
  • Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers.
  • Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.
  • Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market.
2021
  • Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance.
  • Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO.
  • Laurus Labs Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children.
  • Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication.
  • Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.
2022
  • Laurus Labs received purchase orders from a leading Global Life Sciences Company.
2023
  • Laurus Labs received USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment.
  • Laurus Labs signed Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets.
2024
  • Laurus Labs inaugurates new State of the Art R&D facility at IKP Knowledge park.
  • Laurus Labs concludes successful USFDA Audit for API Manufacturing Facility at Hyderabad.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkBuy3690709536.527 Jan 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell3689009536.2327 Jan 2025
ARUN VIJAY NATHANIblockBuy63589430514 Mar 2023
CYBAGE SOFTWARE PRIVATE LIMITEDblockSell63589430514 Mar 2023
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell529337455.414 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy529337455.414 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy529338476.603 Nov 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell529338476.603 Nov 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell210010479.825 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell284783479.825 Oct 2022

Read More

Laurus Labs Ltd News

Laurus Labs to meet investors on June 12

Laurus Labs Limited will hold investor meetings in Hyderabad on June 12, 2026, as part of the Goldman Sachs India CRO/CDMO Tour. No unpublished price sensitive information will be shared.

08 Jun 2026

companies

Laurus Labs files BRSR for FY26

Laurus Labs filed its Business Responsibility and Sustainability Report for FY26, reporting exports at 62.14% of turnover and zero safety incidents.

08 Jun 2026

companies

Laurus Labs promoter group confirms no share encumbrance

Laurus Labs promoter group declares no new share encumbrances in FY26. The disclosure was submitted to stock exchanges on April 07, 2026.

06 Jun 2026

companies

Laurus Labs sets June 10 as record date

Laurus Labs Limited has fixed June 10, 2026, as the record date for dividend payment, subject to shareholder approval at the 21st AGM on July 2, 2026.

06 Jun 2026

companies

Laurus Labs sets July 2 for 21st AGM

Laurus Labs Limited announced its 21st Annual General Meeting will be held via video conferencing on July 2, 2026. The company will dispatch the notice and annual report for FY 2025-26 electronically.

05 Jun 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number